select a format

Single User License
USD 2000 INR 129980
Site License
USD 4000 INR 259960
Corporate User License
USD 6000 INR 389940

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Osteosarcoma-Pipeline Review, H2 2015

Osteosarcoma-Pipeline Review, H2 2015


  • Products Id :- GMDHC7243IDB
  • |
  • Pages: 193
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Osteosarcoma-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Osteosarcoma-Pipeline Review, H2 2015', provides an overview of the Osteosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteosarcoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Osteosarcoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Osteosarcoma Overview 10

Therapeutics Development 11

Pipeline Products for Osteosarcoma-Overview 11

Pipeline Products for Osteosarcoma-Comparative Analysis 12

Osteosarcoma-Therapeutics under Development by Companies 13

Osteosarcoma-Therapeutics under Investigation by Universities/Institutes 15

Osteosarcoma-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Osteosarcoma-Products under Development by Companies 18

Osteosarcoma-Products under Investigation by Universities/Institutes 20

Osteosarcoma-Companies Involved in Therapeutics Development 21

Advaxis, Inc. 21

Amgen Inc. 22

AVEO Pharmaceuticals, Inc. 23

Bayer AG 24

Bellicum Pharmaceuticals, Inc. 25

Celldex Therapeutics, Inc. 26

CytRx Corporation 27

Eleison Pharmaceuticals, Inc. 28

Exelixis, Inc. 29

Isofol Medical AB 30

Merck & Co., Inc. 31

Merrimack Pharmaceuticals, Inc. 32

Neusentis 33

Novartis AG 34

Oncolys BioPharma Inc. 35

Shionogi & Co., Ltd. 36

Sutro Biopharma, Inc. 37

Teijin Pharma Limited 38

United Therapeutics Corporation 39

Osteosarcoma-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Target 41

Assessment by Mechanism of Action 44

Assessment by Route of Administration 47

Assessment by Molecule Type 49

Drug Profiles 51

ADXS-HER2-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

aldoxorubicin hydrochloride-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AM-7209-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

AV-203-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

BL-1249-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

cabozantinib s-malate-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Cell Therapy for GD2 Expressing Solid Tumors-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Cell Therapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

celyvir-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

cisplatin-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

dinutuximab-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

everolimus-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

glembatumumab vedotin-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

irinotecan sucrosofate-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

ISOMC-091-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

LLL-12-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Monoclonal Antibody to Inhibit GD2 for Oncology-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Monoclonal Antibody to Target GD2 for Osteosarcoma-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

OBP-702-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

pazopanib hydrochloride-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

pembrolizumab-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Peptide to Target COX-2 and MAS-GPCR for Oncology-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

radium Ra 223 dichloride-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

RSF-101-Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

S-588410-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

Small Molecules to Inhibit CaMKII for Osteosarcoma-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

Vaccine for Osteosarcoma-Drug Profile 115

Product Description 115

Mechanism of Action 115

R&D Progress 115

Osteosarcoma-Recent Pipeline Updates 116

Osteosarcoma-Dormant Projects 182

Osteosarcoma-Discontinued Products 184

Osteosarcoma-Product Development Milestones 185

Featured News & Press Releases 185

Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2 185

May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 185

May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer 186

Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2 187

Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting 187

Oct 30, 2014: Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study 188

Oct 09, 2014: Eleison Announces Completion of Enrollment in Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer 189

May 27, 2014: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma 189

Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch 190

Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma 191

Appendix 192

Methodology 192

Coverage 192

Secondary Research 192

Primary Research 192

Expert Panel Validation 192

Contact Us 192

Disclaimer 193

List of Tables

Number of Products under Development for Osteosarcoma, H2 2015 11

Number of Products under Development for Osteosarcoma-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd...1) 19

Products under Investigation by Universities/Institutes, H2 2015 20

Osteosarcoma-Pipeline by Advaxis, Inc., H2 2015 21

Osteosarcoma-Pipeline by Amgen Inc., H2 2015 22

Osteosarcoma-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 23

Osteosarcoma-Pipeline by Bayer AG, H2 2015 24

Osteosarcoma-Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 25

Osteosarcoma-Pipeline by Celldex Therapeutics, Inc., H2 2015 26

Osteosarcoma-Pipeline by CytRx Corporation, H2 2015 27

Osteosarcoma-Pipeline by Eleison Pharmaceuticals, Inc., H2 2015 28

Osteosarcoma-Pipeline by Exelixis, Inc., H2 2015 29

Osteosarcoma-Pipeline by Isofol Medical AB, H2 2015 30

Osteosarcoma-Pipeline by Merck & Co., Inc., H2 2015 31

Osteosarcoma-Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 32

Osteosarcoma-Pipeline by Neusentis, H2 2015 33

Osteosarcoma-Pipeline by Novartis AG, H2 2015 34

Osteosarcoma-Pipeline by Oncolys BioPharma Inc., H2 2015 35

Osteosarcoma-Pipeline by Shionogi & Co., Ltd., H2 2015 36

Osteosarcoma-Pipeline by Sutro Biopharma, Inc., H2 2015 37

Osteosarcoma-Pipeline by Teijin Pharma Limited, H2 2015 38

Osteosarcoma-Pipeline by United Therapeutics Corporation, H2 2015 39

Assessment by Monotherapy Products, H2 2015 40

Number of Products by Stage and Target, H2 2015 42

Number of Products by Stage and Mechanism of Action, H2 2015 45

Number of Products by Stage and Route of Administration, H2 2015 48

Number of Products by Stage and Molecule Type, H2 2015 50

Osteosarcoma Therapeutics-Recent Pipeline Updates, H2 2015 116

Osteosarcoma-Dormant Projects, H2 2015 182

Osteosarcoma-Dormant Projects (Contd...1), H2 2015 183

Osteosarcoma-Discontinued Products, H2 2015 184

List of Figures

Number of Products under Development for Osteosarcoma, H2 2015 11

Number of Products under Development for Osteosarcoma-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 40

Number of Products by Top 10 Targets, H2 2015 41

Number of Products by Stage and Top 10 Targets, H2 2015 41

Number of Products by Top 10 Mechanism of Actions, H2 2015 44

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 44

Number of Products by Top 10 Routes of Administration, H2 2015 47

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 47

Number of Products by Top 10 Molecule Types, H2 2015 49

Number of Products by Stage and Top 10 Molecule Types, H2 2015 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advaxis, Inc.

Amgen Inc.

AVEO Pharmaceuticals, Inc.

Bayer AG

Bellicum Pharmaceuticals, Inc.

Celldex Therapeutics, Inc.

CytRx Corporation

Eleison Pharmaceuticals, Inc.

Exelixis, Inc.

Isofol Medical AB

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

Neusentis

Novartis AG

Oncolys BioPharma Inc.

Shionogi & Co., Ltd.

Sutro Biopharma, Inc.

Teijin Pharma Limited

United Therapeutics Corporation

Osteosarcoma Therapeutic Products under Development, Key Players in Osteosarcoma Therapeutics, Osteosarcoma Pipeline Overview, Osteosarcoma Pipeline, Osteosarcoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com